Schonfeld Strategic Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.6K	Buy	+20,920	New	+$36K	﹤0.01%	2391
2023 Q2	–	Sell	-36,643	Closed	-$364K	–	2099
2023 Q1	$364K	Buy	+36,643	New	+$259K	﹤0.01%	1291
2021 Q4	–	Sell	-28,800	Closed	-$253K	–	2101
2021 Q3	$253K	Sell	28,800 -2,194	-7%	-$20.1K	﹤0.01%	1625
2021 Q2	$351K	Buy	30,994 +15,588	+101%	+$187K	﹤0.01%	1375
2021 Q1	$182K	Sell	15,406 -18,248	-54%	-$210K	﹤0.01%	1537
2020 Q4	$232K	Sell	33,654 -74,446	-69%	-$523K	﹤0.01%	1286
2020 Q3	$801K	Sell	108,100 -29,500	-21%	-$191K	0.02%	763
2020 Q2	$574K	Buy	+137,600	New	+$503K	0.01%	763

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Schonfeld Strategic Advisors's ALDX Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Aldeyra Therapeutics (ALDX) in Q2 2026: 20,920 shares worth $44.6K. The stake represents ﹤0.01% of the portfolio and ranks #2391 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ALDX as recently as Q1 2023.

Schonfeld Strategic Advisors first reported a position in ALDX in Q2 2020 and has held it in 8 quarters since. The position peaked at $801K in Q3 2020. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Schonfeld Strategic Advisors held 20,920 shares of Aldeyra Therapeutics worth $44.6K as of Q2 2026.
Aldeyra Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
Aldeyra Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #2391 holding.
Schonfeld Strategic Advisors first reported a position in Aldeyra Therapeutics in Q2 2020 and has held it in 8 quarters since.
Schonfeld Strategic Advisors's Aldeyra Therapeutics position peaked at $801K in Q3 2020.
107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.